Market Cap ₹2636 Cr.
Stock P/E 26.9
P/B 2.6
Current Price ₹460.7
Book Value ₹ 176.4
Face Value 10
52W High ₹590
Dividend Yield 0%
52W Low ₹ 444
INNOVA CAPTAB is an integrated pharmaceutical company in India that was established in 2006. Present across every horizontal of pharmaceutical value chain including research and development, manufacturing, distribution, marketing and exports. Their diversified portfolio consists of branded generic products in numerous therapeutic areas such as cephalosporins, proton pump inhibitors, antidiabetic, cardiovascular, and anticold. It is the second largest domestic formulations CDMO (contract development and manufacturing organization) in India, with a network of over 150,000 retailers, 5,000 stockists and distributors, and 200 products registered with international authorities1. It has world class manufacturing facilities with DSIR recognized research and development laboratory. Their aim is to become the leading global player in the pharmaceutical industry by providing high quality, affordable, and innovative solutions to their customers.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2022 | Dec 2022 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|
| Net Sales | 242 | 242 | 283 | 302 |
| Other Income | 2 | 3 | 3 | 2 |
| Total Income | 244 | 245 | 286 | 305 |
| Total Expenditure | 211 | 208 | 242 | 258 |
| Operating Profit | 33 | 37 | 44 | 47 |
| Interest | 5 | 6 | 9 | 7 |
| Depreciation | 3 | 3 | 5 | 5 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 |
| Profit Before Tax | 25 | 28 | 30 | 35 |
| Provision for Tax | 6 | 9 | 7 | 10 |
| Profit After Tax | 19 | 20 | 23 | 25 |
| Adjustments | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 19 | 20 | 23 | 25 |
| Adjusted Earnings Per Share | 3.9 | 4.1 | 4.8 | 4.4 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|
| Net Sales | 356 | 373 | 411 | 801 | 926 | 1069 |
| Other Income | 0 | 1 | 1 | 3 | 9 | 10 |
| Total Income | 356 | 375 | 412 | 803 | 936 | 1080 |
| Total Expenditure | 315 | 322 | 356 | 705 | 813 | 919 |
| Operating Profit | 41 | 52 | 56 | 99 | 123 | 161 |
| Interest | 6 | 5 | 4 | 6 | 20 | 27 |
| Depreciation | 11 | 10 | 6 | 8 | 11 | 16 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 25 | 38 | 46 | 86 | 92 | 118 |
| Provision for Tax | 5 | 10 | 12 | 22 | 24 | 32 |
| Profit After Tax | 20 | 28 | 35 | 64 | 68 | 87 |
| Adjustments | 0 | -0 | -0 | -0 | -0 | 0 |
| Profit After Adjustments | 20 | 28 | 34 | 64 | 68 | 87 |
| Adjusted Earnings Per Share | 4.2 | 5.8 | 7.2 | 13.3 | 14.1 | 17.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 16% | 35% | 0% | 0% |
| Operating Profit CAGR | 24% | 33% | 0% | 0% |
| PAT CAGR | 6% | 34% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 28% | 30% | 29% | 29% |
| ROCE Average | 24% | 28% | 26% | 26% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Shareholder's Funds | 82 | 110 | 145 | 209 | 277 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 26 | 12 | 6 | 67 | 134 |
| Other Non-Current Liabilities | 2 | 3 | 38 | 21 | 60 |
| Total Current Liabilities | 117 | 129 | 215 | 315 | 278 |
| Total Liabilities | 228 | 254 | 404 | 612 | 748 |
| Fixed Assets | 78 | 73 | 79 | 183 | 183 |
| Other Non-Current Assets | 1 | 1 | 55 | 29 | 123 |
| Total Current Assets | 148 | 180 | 270 | 400 | 442 |
| Total Assets | 228 | 254 | 404 | 612 | 748 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 1 | 2 | 5 | 0 |
| Cash Flow from Operating Activities | 19 | 31 | 42 | 59 | 67 |
| Cash Flow from Investing Activities | -9 | -6 | -20 | -188 | -91 |
| Cash Flow from Financing Activities | -9 | -23 | -19 | 125 | 27 |
| Net Cash Inflow / Outflow | 1 | 1 | 3 | -5 | 3 |
| Closing Cash & Cash Equivalent | 1 | 2 | 5 | 0 | 4 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.15 | 5.81 | 7.17 | 13.29 | 14.15 |
| CEPS(Rs) | 6.36 | 7.91 | 8.35 | 14.89 | 16.46 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 17.18 | 22.99 | 30.17 | 43.46 | 57.61 |
| Core EBITDA Margin(%) | 11.46 | 13.62 | 13.24 | 11.88 | 12.06 |
| EBIT Margin(%) | 8.52 | 11.27 | 12.21 | 11.31 | 11.86 |
| Pre Tax Margin(%) | 6.96 | 10.03 | 11.26 | 10.6 | 9.74 |
| PAT Margin (%) | 5.58 | 7.46 | 8.38 | 7.91 | 7.21 |
| Cash Profit Margin (%) | 8.58 | 10.15 | 9.74 | 8.84 | 8.39 |
| ROA(%) | 8.72 | 11.57 | 10.48 | 12.58 | 9.99 |
| ROE(%) | 24.1 | 28.92 | 27.04 | 36.19 | 28.02 |
| ROCE(%) | 19.63 | 26.48 | 28.42 | 30.64 | 24.34 |
| Receivable days | 93.14 | 86.65 | 99.91 | 79.3 | 92.58 |
| Inventory Days | 39.71 | 50.85 | 69.58 | 49.63 | 47.6 |
| Payable days | 101.39 | 108.78 | 122.96 | 88.6 | 100.16 |
| PER(x) | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.23 | 0.16 | 0.11 | 0.26 | 0.29 |
| EV/Core EBITDA(x) | 2.01 | 1.16 | 0.81 | 2.1 | 2.15 |
| Net Sales Growth(%) | 0 | 4.92 | 10 | 94.94 | 15.72 |
| EBIT Growth(%) | 0 | 38.95 | 19.25 | 81.81 | 22.28 |
| PAT Growth(%) | 0 | 40.3 | 23.72 | 85.37 | 6.26 |
| EPS Growth(%) | 0 | 39.89 | 23.53 | 85.3 | 6.45 |
| Debt/Equity(x) | 0.87 | 0.48 | 0.31 | 0.95 | 0.85 |
| Current Ratio(x) | 1.26 | 1.39 | 1.26 | 1.27 | 1.59 |
| Quick Ratio(x) | 0.93 | 0.89 | 0.83 | 0.86 | 1.17 |
| Interest Cover(x) | 5.44 | 9.11 | 12.8 | 16.09 | 5.6 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 |
| # | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|
| Promoter | 50.9 | 50.9 | 50.9 |
| FII | 3.57 | 3.57 | 1.94 |
| DII | 11.73 | 10.31 | 20.77 |
| Public | 33.8 | 35.22 | 26.39 |
| Others | 0 | 0 | 0 |
| Total | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|
| Promoter | 2.91 | 2.91 | 2.91 |
| FII | 0.2 | 0.2 | 0.11 |
| DII | 0.67 | 0.59 | 1.19 |
| Public | 1.93 | 2.02 | 1.51 |
| Others | 0 | 0 | 0 |
| Total | 5.72 | 5.72 | 5.72 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
